Biotech "Tweets of the Week"
A Crash, a surge, and some FDA drama...just an ordinary week in biotech
(November 16-20, 2015)
Featuring:
$ADAP $AGN $AZN $BMRN $CLLS $CLVS $DEPO $GNFT $HZNP $KBIO $PFE $PTCT $RDUS $RLYP $SRPT $VRTX $VRX $XBI $IBB
Looking for past biotech highlights? Check out the Biotech Tweets of the Week archive.
Clovis Stumbles on Disappointing Data Update $CLVS $AZN
FDA wants more info from $CLVS from mid cycle review
— zach (@zbiotech) November 16, 2015
$CLVS: #FDA request on additional info may delay potential approval/could extend March 30 PDUFA
https://t.co/W6K9qglXuJ
#pharma #biotech
— Donna Young (@ScripDonnaDC) November 16, 2015
Remember when the Street believed $CLVS knew what it was doing and $AZN was the bumbling idiot?
— Adam Feuerstein (@adamfeuerstein) November 16, 2015
$CLVS in a potential registration delay, as if it wasn't enough to compete with $AZN's Iressa salesforce...among other competitive issues
— Juan P. Serrate, DVM (@JPZaragoza1) November 16, 2015
$CLVS Confirmed ORR of 500mg dose: 28%; 625mg: 34%.
Only about half of what's on $AZN Tagrisso (AZD9291) label... pic.twitter.com/C7HR05ByG9
— Andy Biotech (@AndyBiotech) November 16, 2015
"Don't panic" sellside notes coming in 3...2...1 $CLVS
— Jacob Plieth (@JacobPlieth) November 16, 2015
That's going to hurt $CLVS.
— Michael Torres, PhD (@Mykalt45) November 16, 2015
$CLVS has had this info since end of oct, when they submitted the 90d update to the FDA
— zach (@zbiotech) November 16, 2015
convenient $CLVS cut off the call immediately after they acknowledged having the data as of the Q3 EPS call...barely 3 questions deep in Q&A
— zach (@zbiotech) November 16, 2015
This is Astra in London on the $CLVS news. pic.twitter.com/9QAwi0Xbqu
— Brad Loncar (@bradloncar) November 16, 2015
gotta say it is pretty disgusting to read thru $CVLS Q3 transcript knowing mgmt knew what they did of responses pic.twitter.com/OlFmlraFaR
— zach (@zbiotech) November 16, 2015
$AZN has won in value what $CLVS has lost approx. ~$2.3B vs. ~$2.7B
— Juan P. Serrate, DVM (@JPZaragoza1) November 16, 2015
thing that continues to blow my mind is how a guy who has been in this biz for many years thought this kinda thing would fly w/the FDA $CLVS
— zach (@zbiotech) November 16, 2015
$CLVS down 66% after FDA delay for #lungcancer drug rociletinib - analysts were saying friday that they expected early approval
— Lisa LaMotta (@BioWriterChik) November 16, 2015
$CLVS downgraded to Neutral from Conviction Buy at Goldman, PT $23 from $123
— Bio Stocks™ (@BioStocks) November 17, 2015
Let's take another look at those Goldman $CLVS recommendations pic.twitter.com/rJOP2UA5xg
— Jacob Plieth (@JacobPlieth) November 17, 2015
Martin Shkreli's Dumpster Diving Sends KaloBios Soaring $KBIO
The elusive biotech shut-down. $KBIO
KaloBios to Wind Down Operations https://t.co/wmzs4Cq5z4
— PropThink (@PropThinker) November 13, 2015
$KBIO Resumed Trading == $0.10 per share? Any buyers?
— MAISA (@MaisaCorp) November 13, 2015
@BioStocks Martin is buying again? https://t.co/LvYSmun73s
— roy vimer (@roiev123) November 18, 2015
@TomSilver39 and it is happening as I said yesterday $kbio :)
— Tom Silver (@TomSilver39) November 18, 2015
Even if the man is reverse merging the value of a shell is a few million. Gonna be massively diluted folks.
— NathanAaron (@NathanAhron) November 18, 2015
$GBIM up 27% AH on $KBIO news. $GBIM has a smaller float than $KBIO and is looking to reverse merge...Cantor Fitzgerald is financial advisor
— Joel Thomson (@JSTBiotech) November 18, 2015
@BioBreakout the only time a trader won't complain that there were no shares available to short. Wow.
— BioBounce.com (@BioBounce) November 18, 2015
$KBIO
11/16 p/m 0.35
11/18 a/h 18.78
And there's the are-you-f'in-shittin-me trade for 2015.
— S Manian (@DrSManian) November 19, 2015
$KBIO - to continue the company's operations," said Ronald Martell, Executive Chairman of KaloBios. https://t.co/fy3DAj1jDL
— Ospreyeye (@MyChartCoachcom) November 19, 2015
Stay tuned for "Told our members buy $KBIO $2.00 in chat, sold at $15 for 700% gain 2 hrs later, join now!" every sub service ad next 2 wks
— Jean Fonteneau (@JFinDallas) November 19, 2015
$KBIO wraps up ah +824% unfortunately I don't own & fortunately I was not short
— Isaac M (@ymscapital) November 19, 2015
Just my hunch, but Martin and his investors know conventional IPO for Turing can't happen, so merger into $KBIO shell is best option.
— Adam Feuerstein (@adamfeuerstein) November 19, 2015
lots of crap floating to the top today b/c of $KBIO and $CLDN news
— Red Acre Investments (@redacre) November 19, 2015
@mad_scientist2 @adamfeuerstein @martinshkreli Going L you have finite risk, can't lose more than invested. Going S you have infinite risk.
— Jason Napodano, CFA (@JNapodano) November 19, 2015
Theres two types of traders, those that are humble, and those that are about to be. Last night $KBIO humbled me.
— The Daytrade™ (@d4ytrad3) November 19, 2015
KaloBios Surges Seven-Fold After Investment From Martin Shkreli https://t.co/iJ4kiyfOe5 #biotech
— Pharma 411 (@pharma411) November 19, 2015
$KBIO KaloBios Pharmaceuticals, Inc. Appoints Martin Shkreli CEO and Announces New Financing https://t.co/0fOZOtrU5D
— Tom Silver (@TomSilver39) November 20, 2015
Now that @MartinShkreli is CEO of $KBIO, must he disclose investigations, lawsuits, subpoenas related to Turing? Or, can he keep separate?
— Adam Feuerstein (@adamfeuerstein) November 20, 2015
$KBIO this is all shorts and T+3... could go, halt, halt, halt
— Shane Blackmon (@shaneblackmon) November 20, 2015
$KBIO double
— Bio Stocks™ (@BioStocks) November 20, 2015
The financial twitter community (myself included) couldn't have gotten the $KBIO story more wrong. Let's all just shut up.
— Cody (@codytrades) November 20, 2015
Biomarin's Ad Comm Marks Major Chapter in DMD Saga $BMRN $SRPT $PTCT
How to Prepare for $BMRN (and Biotech's) Biggest Event of 2015 https://t.co/4JRlE3KrTa $SRPT
— Adam Feuerstein (@adamfeuerstein) November 18, 2015
2nd ep of #Signal podcast is up! This wk @ldtimmerman & I go into history of drisapersen & eteplirsen. https://t.co/wG9Ptyvkie $BMRN $SRPT
— Meg Tirrell (@megtirrell) November 19, 2015
Today is the last day for $SRPT holders to decide if they want to Reduce/Close position or KEEP holding through $BMRN BD & AdCom on 11/24
— Joe (@GantosJ) November 19, 2015
My entire life I'll remember the 48wk data day in Oct 2012. Hard to believe we are only just now having a meeting 3 years later. $SRPT $BMRN
— Brad Loncar (@bradloncar) November 20, 2015
$srpt between $bmrn briefing docs, adcom+ $srpt briefing docs i expect multiple trading ops/dips, but ultimate adcom vote will be positive.
— Dirk Haussecker (@RNAiAnalyst) November 20, 2015
@GantosJ I would actually love to hear from the kids from the p2 trial of drisa- never have found any of them
— jenn mcnary (@jennmcnary) November 20, 2015
@bradloncar @GantosJ It was really what made me realize the power of Twitter. The stories about the McNary family continue to inspire.
— Timothy Sullivan (@tsullivan70) November 20, 2015
$BMRN adcomm briefing docs are out! https://t.co/eRXCK0k9pJ
— Juan P. Serrate, DVM (@JPZaragoza1) November 20, 2015
$BMRN FDA also asks panel to vote on dystrophin production.
There is no “approval yes or no” question.
— Adam Feuerstein (@adamfeuerstein) November 20, 2015
$BMRN Conclusion of review pic.twitter.com/EPWT1N9zh7
— j l (@bio_clouseau) November 20, 2015
$BMRN board docs out.
In premarket:
$BMRN -6%
$SRPT +8%
— 23aloha (@23aloha) November 20, 2015
FDA..."No agreement has been reached on the design of the confirmatory study in subsequent interactions with Biomarin" $BMRN $SRPT
— zach (@zbiotech) November 20, 2015
$BMRN FDA: "Even in the context of an invariably disabling and fatal disease such as DMD, the safety profile
of drisapersen is concerning"
— Adam Feuerstein (@adamfeuerstein) November 20, 2015
As I follow the insta-analysis of the 387-page FDA brief doc on $BMRN, I'm wondering if those speed-reading courses are finally paying off.
— Michael Gilman (@michael_gilman) November 20, 2015
$34 is still cheap if $SRPT becomes the only game in town guys...
— Zachary Prensky (@Zackfoot) November 20, 2015
$SRPT Booyah!
— BioBreakout (@BioBreakout) November 20, 2015
$BMRN $GSK Prosensa never disclosed the severity of drisa toxicity. This is really bad.
— Adam Feuerstein (@adamfeuerstein) November 20, 2015
@adamfeuerstein DING DING DING DING DING! There is no drug where I need to see briefing docs more than $SRPT.
— Matthew Herper (@matthewherper) November 20, 2015
@AndyBiotech yeah this is a big time red flag for $PTCT
— Red Acre Investments (@redacre) November 20, 2015
$PTCT -8% in sympathy on $BMRN drisa review.
— Adam Feuerstein (@adamfeuerstein) November 20, 2015
did $BMRN hire that $VNDA consultant? //just wondering
— Red Acre Investments (@redacre) November 20, 2015
@Ogut_Ozgur Remains a big risk for $SRPT. Bookmark your tweet.
— Adam Feuerstein (@adamfeuerstein) November 20, 2015
It’s been an exciting morning!
Remember, I will be live-blogging the $BMRN FDA panel on Tuesday. I hope everyone logs in. Link TBA.
— Adam Feuerstein (@adamfeuerstein) November 20, 2015
Seen on the stream...
French biotech seems to be holding up OK $ALCLS $GNFT $ALONC $ALSEN
— Tony Friedman (@zzlangerhans) November 16, 2015
Our zealotry for quality metrics puts the government verse men's health https://t.co/qDMKYyn1Ej
— daviesbj (@daviesbj) November 16, 2015
Genfit set to start Phase III study of elafibranor in NASH; sees possible 2019 launch https://t.co/bRwEgjdzIp $GNFT #pharma
— FirstWord Pharma (@fwpharma) November 16, 2015
$CFRX Sold at open for a quick 5% gain from last week; will look to re-enter EoDec.
— Jason (@JasonHolman5) November 16, 2015
2,000% price hike for infant seizure drug called "absurd" https://t.co/82IQhMRTxJ via @yahoocanadanews $MNK
— Charley Grant (@CGrantWSJ) November 16, 2015
$RLYP Lets be honest, whether you like it or not someone (institution) is shorting this successfully. It wont be like this forever
— Tony (@tony__teo) November 16, 2015
The $NLNK $MRK Ebola vaccine won "grand award" in Popular Science's 100 greatest innovations issue. pic.twitter.com/M4yipsbjDd
— Brad Loncar (@bradloncar) November 17, 2015
$GNFTF finally disclosed ITT primary endpoint result (NASH resolution) from GOLDEN study: Placebo 17% Elafibranor 21% p value 0.28
— Adam Feuerstein (@adamfeuerstein) November 17, 2015
$SRPT Eteplirsen vs historical control data published in Ann. Neurol
https://t.co/3od1ZN0QcX $BMRN #Duchenne pic.twitter.com/UQYiZMMhLu
— Andy Biotech (@AndyBiotech) November 17, 2015
Very, very few women appear to want Valeant's female libido pill: https://t.co/O21hnLLnEg via @annaedney $VRX
— Drew Armstrong (@ArmstrongDrew) November 17, 2015
Remember how we used to say that $BLUE's oncology program was given $0 value. Think that's changing now.
— Brad Loncar (@bradloncar) November 17, 2015
#RobertCaliff says believes #FDA can have impact on costs of drugs, but it's "not our job" to set price of drugs.
#Califf #FDA #drugprices
— Donna Young (@ScripDonnaDC) November 17, 2015
$RDUS Stat plan change, BTD denied twice and now stability data pic.twitter.com/JbHicZtWQB
— j l (@bio_clouseau) November 17, 2015
Califf tells Senate he won't lower FDA standards.."If anything, I've argued for raising them" https://t.co/ZYwW3IPLGH #pharma #FDA
— pharmalot (@pharmalot) November 17, 2015
It's early, and I don't think anyone will care for quite a while, but $ARWR is making real progress in understanding of HBV. No position
— Jake King (@FajaJake) November 17, 2015
$HZNP may have had a 5% (generous) chance of success for hostile bid, now its just burnt toast.
$DEPO.
— happyycamperr (@happyycamperr) November 17, 2015
Hey, big spender! Global #drug spending to hit $1.4 trillion in 2020: IMS https://t.co/qwD4Im2fHs
— Ben Hirschler (@reutersBenHir) November 18, 2015
JMP $DEPO PT 28 $DEPO announced acquisition of U.S&Canadian rights to cebranopadol late-stage,first-in-class pain candidate from Grünenthal
— dough (@tgtxdough) November 18, 2015
$VRTX Vertex receives 2 EU approvals for Kalydeco. https://t.co/7pLe6iA2h2
— Chill Till (@ChillzTrading) November 18, 2015
Re manufacturing $KITE CEO also stressed modular nature of commercial plant - can be expanded easily.
— Jacob Plieth (@JacobPlieth) November 18, 2015
$bmrn $blue $ incy $kite all get buy ratings from $gs this morning. But $sgen gets a sell.
— Joe (@Drchik23) November 18, 2015
$ADAP CEO confident that the paused esophagus cancer clinical trial will resume shortly.
— vlad33301 (@vlad33301) November 18, 2015
$ADAP CEO: Patient death in halted NY-ESO esophageal study: not caused by off-target effect cf MAGE-A3. Not cytokline storm cc @bradloncar
— Jacob Plieth (@JacobPlieth) November 18, 2015
@bradloncar @JacobPlieth indeed! Great stuff, Jacob
— Michael Gladstone (@MikeNGladstone) November 18, 2015
Alzheimer's field is so desperate anything remotely showing benefit will get nod from FDA. Doesn't make drug great. Makes the need great.
— BlackbirdHoldings (@kokurasluck) November 18, 2015
57.7% of Opdivo patients in CheckMate -066 alive at two years vs 26.7% on dacarbazine. $BMY https://t.co/8DG6ixg2E4
— Brad Loncar (@bradloncar) November 18, 2015
Honest question. Why are bidders lining up for $ZSPH while $RLYP languishes at 1/3rd the value? HF's and biotech's see it, Twitter doesn't.
— Shane Blackmon (@shaneblackmon) November 18, 2015
Yesterday I tweeted a snarky comment about $HALO. The company was nice enough to reach out and correct the record. pic.twitter.com/ywNpMjPsvc
— Brad Loncar (@bradloncar) November 18, 2015
Radius CEO Says Drug Application Delayed for `Work-Life Balance' https://t.co/MaHoTvc3R1 via @donibloomfield
— Caroline Chen (@CarolineYLChen) November 18, 2015
@bio_clouseau Most interesting tidbits: all 3 parties either withdrew bid or lower bid after further dd and $RLYP approval.
— JQ (@jq1234t) November 18, 2015
@dsobek Is that an acknowledgment that they do not think they can stop a $PFE/$AGN deal and this is face saving or something else?
— David Sobek (@dsobek) November 18, 2015
Congrats Liz Blackburn. UCSF's loss is the Salk's gain! https://t.co/dm2AXap5o5
— Ethan Weiss (@ethanjweiss) November 18, 2015
One of those days where position size is reeeally important
— Randy (@lipscrl) November 19, 2015
Good news for Cellectis as Servier opts in $CLLS $ALCLS
— Juan P. Serrate, DVM (@JPZaragoza1) November 19, 2015
UnitedHealth basically questioning whether they can make it in the Obamacare biz $UNH: pic.twitter.com/B4XYOjOhef
— Drew Armstrong (@ArmstrongDrew) November 19, 2015
Waving White Flag, Celladon Merges With Rare Disease Co. Eiger Bio https://t.co/F8OkBFDP5q $CLDN $QURE $ONCE $BLUE #GeneTherapy
— Ben Fidler (@BentheFidler) November 19, 2015
Uber is delivering flu shots today. One day only. https://t.co/R42qxciMZc
— Charles Ornstein (@charlesornstein) November 19, 2015
@lamSanjayGupta @srqstockpicker pigeons have a glorious history in behavioral sciences
— Alfredo Fontanini (@AF_biotech) November 19, 2015
$CLDN closed unchanged after being up 170% in premarket.... blink, and nothing happened
— Shane Blackmon (@shaneblackmon) November 19, 2015
Here is an update of the spreadsheet that shows $IBB stocks vs their 52 week highs. https://t.co/foBYkae8Ti
— Brad Loncar (@bradloncar) November 19, 2015
$HZNP withdrawing offer for $DEPO
— Caroline Chen (@CarolineYLChen) November 20, 2015
@OpenOutcrier re $vrx citi put overweight rating on them
— Isaac M (@ymscapital) November 19, 2015
Th17 approach: $VTAE Announces Positive Top Line Results From A Phase 1 Multiple Ascending Dose Trial Of VTP 43742 https://t.co/nXsnQDoA5h
— Bruce Booth (@LifeSciVC) November 20, 2015
@adamfeuerstein biotech rule no. 15: Europe approves everything, but who outside Germany gonna pay for it? $vrtx
— Dirk Haussecker (@RNAiAnalyst) November 20, 2015
$AEZS 1:100 R/S effective.
— Bio Stocks™ (@BioStocks) November 20, 2015
$AAVL names Paul Cleveland (ex $CLDN CEO) as new CEO.
— Bio Stocks™ (@BioStocks) November 20, 2015
$apto clinical hold
— Joe (@Drchik23) November 20, 2015
I'm proud to be part of a team that produced this submission to NICE in relation to #Orkambi for people with #CF: https://t.co/zysrevgaEq
— Oli Rayner (@oli_rayner) November 20, 2015
I know we’re 100% $BMRN $SRPT, but resignation of $MNKD CEO is pretty incredible news this morning. Al Mann stepping in as interim CEO? Eek!
— Adam Feuerstein (@adamfeuerstein) November 20, 2015
Some (+) %
$KBIO +30%
$SRPT +24
$ANF +18
$OCN +12
$HIBB +12
$INTU +10
$HART +10
$ROST +8
$SQ +6
$CAB +6
$HABT +6
$FL +5
$NKE +4
$SPLK +3
— Tom Wrigley (@WrigleyTom) November 20, 2015
I'm sure a new CEO will make all the difference at $MNKD
— Jon Gardner (@ByJonGardner) November 20, 2015